Alkermes (ALKS)
(Delayed Data from NSDQ)
$23.40 USD
+0.19 (0.82%)
Updated May 31, 2024 04:00 PM ET
After-Market: $23.39 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth C Momentum A VGM
Brokerage Reports
Alkermes plc [ALKS]
Reports for Purchase
Showing records 21 - 40 ( 288 total )
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
3Q Shows Some Softness, Though "New" Alkermes Comes Into Focus; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
With Janssen Win as a Tailwind, Core Portfolio Delivers Another Quarter of Growth
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Alkermes Reiterates Financial Expectations for 2023 Despite Softer 1Q, Pipeline Makes Progress; PT Up to $34
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Alkermes Sets Three Big Goals for 2023; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department